ATE399556T1 - Transfusionszubereitung zur peripheren intravenösen verabreichung und verfahren zur stabilisierung von vitamin b1 - Google Patents

Transfusionszubereitung zur peripheren intravenösen verabreichung und verfahren zur stabilisierung von vitamin b1

Info

Publication number
ATE399556T1
ATE399556T1 AT04733089T AT04733089T ATE399556T1 AT E399556 T1 ATE399556 T1 AT E399556T1 AT 04733089 T AT04733089 T AT 04733089T AT 04733089 T AT04733089 T AT 04733089T AT E399556 T1 ATE399556 T1 AT E399556T1
Authority
AT
Austria
Prior art keywords
infusion
intravenous administration
peripheral intravenous
transfusion preparation
stabilizing vitamin
Prior art date
Application number
AT04733089T
Other languages
English (en)
Inventor
Yasuhiro Mitsumoto
Shigeaki Arita
Seiji Tani
Nobuaki Sumiyoshi
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of ATE399556T1 publication Critical patent/ATE399556T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
AT04733089T 2003-05-22 2004-05-14 Transfusionszubereitung zur peripheren intravenösen verabreichung und verfahren zur stabilisierung von vitamin b1 ATE399556T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003145353 2003-05-22

Publications (1)

Publication Number Publication Date
ATE399556T1 true ATE399556T1 (de) 2008-07-15

Family

ID=33475233

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04733089T ATE399556T1 (de) 2003-05-22 2004-05-14 Transfusionszubereitung zur peripheren intravenösen verabreichung und verfahren zur stabilisierung von vitamin b1

Country Status (11)

Country Link
US (1) US20060211631A1 (de)
EP (1) EP1632233B1 (de)
JP (1) JP4594232B2 (de)
KR (1) KR101039224B1 (de)
CN (1) CN100486579C (de)
AT (1) ATE399556T1 (de)
AU (1) AU2004241840B2 (de)
CA (1) CA2526208C (de)
DE (1) DE602004014760D1 (de)
TW (1) TWI331043B (de)
WO (1) WO2004103375A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI319984B (en) * 2003-06-06 2010-02-01 Sterile combined preparation
JP5554466B2 (ja) 2004-03-01 2014-07-23 味の素株式会社 抗ヒトＴＮＦ−α抗体活性低下抑制剤
JP4894219B2 (ja) * 2004-10-15 2012-03-14 ニプロ株式会社 ビタミンｂ群配合末梢静脈栄養輸液
US8148356B2 (en) * 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
AU2011202871B2 (en) * 2005-08-24 2014-06-12 Cumberland Pharmaceuticals Inc. Acetylcysteine composition and uses therefor
WO2007055312A1 (ja) * 2005-11-10 2007-05-18 Mitsubishi Tanabe Pharma Corporation ピラゾロン化合物含有水溶液が充填されたプラスチック容器
JPWO2008146731A1 (ja) * 2007-05-25 2010-08-19 味の素株式会社 末梢静脈投与用輸液の製造方法
WO2008146732A1 (ja) * 2007-05-25 2008-12-04 Ajinomoto Co., Inc. 末梢静脈投与用輸液
AU2009268742C1 (en) 2008-07-07 2013-11-28 Pentec Health, Inc. Nutritive compositions and methods of using same
AU2013207545B2 (en) * 2008-07-07 2015-06-18 Pentec Health, Inc. Nutritive compositions and methods of using same
WO2010104023A1 (ja) * 2009-03-11 2010-09-16 味の素株式会社 ビタミンｂ１を安定に配合した糖液を含む末梢静脈投与用輸液
KR20120125487A (ko) * 2010-01-04 2012-11-15 펜텍 헬스 인코포레이티드 영양 조성물 및 이를 사용하는 방법
CN102869362A (zh) * 2010-05-07 2013-01-09 味之素株式会社 混合有维生素的外周静脉给药用营养输液
CN103237541A (zh) 2010-11-29 2013-08-07 株式会社大塚制药工场 输液制剂
CN105412896B (zh) * 2016-01-06 2021-08-31 鲁南制药集团股份有限公司 一种避免安神补脑液中维生素b1含量下降的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5916817A (ja) * 1982-07-16 1984-01-28 Eisai Co Ltd アミノ酸輸液
JPH06312923A (ja) * 1993-04-30 1994-11-08 Green Cross Corp:The 末梢静脈投与用栄養輸液
JP2990686B2 (ja) * 1994-11-17 1999-12-13 田辺製薬株式会社 水溶性ビタミンｂ類配合総合輸液
JPH0959150A (ja) * 1995-08-11 1997-03-04 Roussel Morishita Kk 経静脈用輸液製剤
JP3824716B2 (ja) * 1996-09-17 2006-09-20 株式会社大塚製薬工場 中心静脈投与用輸液
JP3771644B2 (ja) * 1996-09-17 2006-04-26 株式会社大塚製薬工場 末梢静脈投与用輸液
JP4178563B2 (ja) * 1997-07-18 2008-11-12 味の素株式会社 ２室容器入りビタミンｂ１配合栄養輸液剤
JP4162306B2 (ja) * 1997-09-25 2008-10-08 株式会社大塚製薬工場 中心静脈投与用輸液
TW367247B (en) * 1998-02-03 1999-08-21 Otsuka Pharma Co Ltd Storage container for Vitamin D solution and transfusion container
JP4767375B2 (ja) * 1999-03-19 2011-09-07 田辺三菱製薬株式会社 総合輸液剤
JP4101418B2 (ja) * 1999-12-03 2008-06-18 田辺三菱製薬株式会社 総合栄養輸液剤
US6391332B1 (en) * 2000-04-20 2002-05-21 Baxter International, Inc. Therapeutic micronutrient composition for severe trauma, burns and critical illness
JP2003055195A (ja) * 2001-08-20 2003-02-26 Terumo Corp ビタミンｂ１配合末梢静脈投与用総合輸液剤
JP2006001945A (ja) * 2005-09-01 2006-01-05 Terumo Corp ビタミンｂ１配合末梢静脈投与用総合輸液剤

Also Published As

Publication number Publication date
TW200501931A (en) 2005-01-16
CN100486579C (zh) 2009-05-13
DE602004014760D1 (de) 2008-08-14
AU2004241840A1 (en) 2004-12-02
EP1632233B1 (de) 2008-07-02
CA2526208C (en) 2011-11-08
JP4594232B2 (ja) 2010-12-08
AU2004241840B2 (en) 2010-02-25
EP1632233A4 (de) 2006-05-31
CA2526208A1 (en) 2004-12-02
JPWO2004103375A1 (ja) 2006-07-20
KR101039224B1 (ko) 2011-06-03
CN1777428A (zh) 2006-05-24
EP1632233A1 (de) 2006-03-08
US20060211631A1 (en) 2006-09-21
KR20060015584A (ko) 2006-02-17
TWI331043B (en) 2010-10-01
WO2004103375A1 (ja) 2004-12-02

Similar Documents

Publication Publication Date Title
ATE399556T1 (de) Transfusionszubereitung zur peripheren intravenösen verabreichung und verfahren zur stabilisierung von vitamin b1
DE69824861D1 (de) Glukose enthaltende zubereitung
DK179286D0 (da) Insulinpraeparat
DE2260189A1 (de) Injizierbare aminosaeurepraeparate
DE3687501D1 (de) Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eines arneimittels zur behandlung von komplikationen bei diabetes mellitus.
CN108472339A (zh) 利用甲硫氨酸和天冬酰胺消耗对包括人类在内的哺乳动物进行癌症治疗的方法
PT87658A (pt) Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet loesung enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin
EP1479393A4 (de) Stabilisierte albumin-zubereitungen
Lo et al. Interaction of human hemoglobin with adenine nucleotides
SE9300105D0 (sv) Stable protein solution
KR880012235A (ko) 정상 포유동물의 헤마토크릿을 증가시키는 방법
EP1425047A4 (de) Verfahren zur verbesserung des sauerstofftransports mit erythrozyten-konserven
Gunnison et al. Species variability in plasma S-sulfonate levels during and following sulfite administration
Furuta et al. Secretin-like activity of dopamine on canine pancreatic secretion
Oertel et al. A simple method for the determination of articaine and its metabolite articainic acid in dentistry: application to a comparison of articaine and lidocaine concentrations in alveolus blood
Traylor et al. Reactivity of ferrous heme proteins at low pH.
Hangai-Hoger et al. Microvascular oxygen delivery and consumption following treatment with verapamil
CN101204371B (zh) 一种注射用维生素c钠水针及其制备方法
Sutoo et al. The mechanism by which calcium reduces blood pressure
Gillette et al. Preliminary clinical trials with cyanate
Lotspeich Kidney, water and electrolyte metabolism
MXPA00006934A (es) Uso de derivados de hemoglobina para determinar el volumen plasmatico y/o sanguineo.
SU1739295A1 (ru) Способ определени стимулирующего действи фармпрепаратов на кислородсв зывающую функцию крови
Langbroek et al. Changes in Arterial Carbon Dioxide Tension and Arterio-Venous Difference in Oxygen Content with pH during Metabolic Acidosis
RU99114404A (ru) Способ лечения увеитов

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties